World Pharma News Digest - 10.06.2014
4 views
Skip to first unread message
Ruslan David
Jun 10, 2014, 5:52:19 AM6/10/14
to worldph...@googlegroups.com
Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) have announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).
Read more...
http://www.worldpharmanews.com/sanofi/2797-sanofi-and-lilly-announce-licensing-agreement-for-cialisr-tadalafil-otc
Design of self-assembling protein nanomachines starts to click
A route for constructing protein nanomachines engineered for specific applications may be closer to reality. Biological systems produce an incredible array of self-assembling, functional protein tools. Some examples of these nanoscale protein materials are scaffolds to anchor cellular activities, molecular motors to drive physiological events, and capsules for delivering viruses into host cells.
Read more...
http://www.worldpharmanews.com/research/2796-design-of-self-assembling-protein-nanomachines-starts-to-click
International committee re-defines how multiple sclerosis is described and understood
Multiple sclerosis manifests itself in many different ways and different courses. A recent effort to fine-tune descriptions - or phenotypes - of MS was undertaken by an international team of leaders in MS research and clinical care. The results of this effort by the International Advisory Committee on Clinical Trials in MS, including recommendations for more research, has just been published (Neurology 2014;83:1).
Read more...
http://www.worldpharmanews.com/research/2795-international-committee-re-defines-how-multiple-sclerosis-is-described-and-understood
Bristol-Myers Squibb and Syngene International extend research collaboration
Bristol-Myers Squibb (NYSE:BMY) and Syngene International, India's largest contract research organization, have announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
Read more...
http://www.worldpharmanews.com/bms/2794-bristol-myers-squibb-and-syngene-international-extend-research-collaboration
Anti-diabetic drug slows aging and lengthens lifespan
A study by Belgian doctoral researcher Wouter De Haes (KU Leuven) and colleagues provides new evidence that metformin, the world's most widely used anti-diabetic drug, slows ageing and increases lifespan. In experiments reported in the journal Proceedings of the National Academy of Sciences, the researchers tease out the mechanism behind metformin's age-slowing effects: the drug causes an increase in the number of toxic oxygen molecules released in the cell and this, surprisingly, increases cell robustness and longevity in the long term.
Read more...
http://www.worldpharmanews.com/research/2793-anti-diabetic-drug-slows-aging-and-lengthens-lifespan
AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 June 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Read more...
http://www.worldpharmanews.com/astrazeneca/2792-astrazeneca-updates-on-the-rapid-progress-of-its-oncology-pipeline-at-asco-2014
Bayer and Orion Corporation to develop and commercialize novel prostate cancer treatment
Bayer has entered into a global agreement with Orion Corporation, a pharmaceutical company based in Espoo, Finland, (Nasdaq OMX Helsinki: ORNAV and ORNBV) for the development and commercialization of the compound ODM-201, an investigational novel oral androgen receptor inhibitor. ODM-201 is in clinical development for the treatment of patients with prostate cancer.
Read more...
http://www.worldpharmanews.com/bayer/2791-bayer-and-orion-corporation-to-develop-and-commercialize-novel-prostate-cancer-treatment
PharmaNews.eu / Latest News
Molecular 'scaffold' could hold key to new dementia treatments
http://www.pharmanews.eu/research-and-development/1447-molecular-scaffold-could-hold-key-to-new-dementia-treatments
Pharmacists develop three new drug candidates against inflammation
http://www.pharmanews.eu/research-and-development/1448-pharmacists-develop-three-new-drug-candidates-against-inflammation
Antibiotic crisis needs united global response, experts say
http://www.pharmanews.eu/research-and-development/1449-antibiotic-crisis-needs-united-global-response-experts-say
Finnish researchers discovered a new anticancer compound using accelerated drug screening process
http://www.pharmanews.eu/research-and-development/1446-finnish-researchers-discovered-a-new-anticancer-compound-using-accelerated-drug-screening-process
Biovision presents its selection of 44 promising life sciences businesses and projects
http://www.pharmanews.eu/conferences-and-events/1445-biovision-presents-its-selection-of-44-promising-life-sciences-businesses-and-projects
AstraZeneca and MRC Laboratory of Molecular Biology to launch joint research fund
http://www.pharmanews.eu/astrazeneca/1444-astrazeneca-and-mrc-laboratory-of-molecular-biology-to-launch-joint-research-fund
Shark antibodies inspire optimization of human antibodies
http://www.pharmanews.eu/research-and-development/1442-shark-antibodies-inspire-optimization-of-human-antibodies
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) have announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).
Read more...
http://www.worldpharmanews.com/sanofi/2797-sanofi-and-lilly-announce-licensing-agreement-for-cialisr-tadalafil-otc
Design of self-assembling protein nanomachines starts to click
A route for constructing protein nanomachines engineered for specific applications may be closer to reality. Biological systems produce an incredible array of self-assembling, functional protein tools. Some examples of these nanoscale protein materials are scaffolds to anchor cellular activities, molecular motors to drive physiological events, and capsules for delivering viruses into host cells.
Read more...
http://www.worldpharmanews.com/research/2796-design-of-self-assembling-protein-nanomachines-starts-to-click
International committee re-defines how multiple sclerosis is described and understood
Multiple sclerosis manifests itself in many different ways and different courses. A recent effort to fine-tune descriptions - or phenotypes - of MS was undertaken by an international team of leaders in MS research and clinical care. The results of this effort by the International Advisory Committee on Clinical Trials in MS, including recommendations for more research, has just been published (Neurology 2014;83:1).
Read more...
http://www.worldpharmanews.com/research/2795-international-committee-re-defines-how-multiple-sclerosis-is-described-and-understood
Bristol-Myers Squibb and Syngene International extend research collaboration
Bristol-Myers Squibb (NYSE:BMY) and Syngene International, India's largest contract research organization, have announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
Read more...
http://www.worldpharmanews.com/bms/2794-bristol-myers-squibb-and-syngene-international-extend-research-collaboration
Anti-diabetic drug slows aging and lengthens lifespan
A study by Belgian doctoral researcher Wouter De Haes (KU Leuven) and colleagues provides new evidence that metformin, the world's most widely used anti-diabetic drug, slows ageing and increases lifespan. In experiments reported in the journal Proceedings of the National Academy of Sciences, the researchers tease out the mechanism behind metformin's age-slowing effects: the drug causes an increase in the number of toxic oxygen molecules released in the cell and this, surprisingly, increases cell robustness and longevity in the long term.
Read more...
http://www.worldpharmanews.com/research/2793-anti-diabetic-drug-slows-aging-and-lengthens-lifespan
AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 June 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Read more...
http://www.worldpharmanews.com/astrazeneca/2792-astrazeneca-updates-on-the-rapid-progress-of-its-oncology-pipeline-at-asco-2014
Bayer and Orion Corporation to develop and commercialize novel prostate cancer treatment
Bayer has entered into a global agreement with Orion Corporation, a pharmaceutical company based in Espoo, Finland, (Nasdaq OMX Helsinki: ORNAV and ORNBV) for the development and commercialization of the compound ODM-201, an investigational novel oral androgen receptor inhibitor. ODM-201 is in clinical development for the treatment of patients with prostate cancer.
Read more...
http://www.worldpharmanews.com/bayer/2791-bayer-and-orion-corporation-to-develop-and-commercialize-novel-prostate-cancer-treatment
PharmaNews.eu / Latest News
Molecular 'scaffold' could hold key to new dementia treatments
http://www.pharmanews.eu/research-and-development/1447-molecular-scaffold-could-hold-key-to-new-dementia-treatments
Pharmacists develop three new drug candidates against inflammation
http://www.pharmanews.eu/research-and-development/1448-pharmacists-develop-three-new-drug-candidates-against-inflammation
Antibiotic crisis needs united global response, experts say
http://www.pharmanews.eu/research-and-development/1449-antibiotic-crisis-needs-united-global-response-experts-say
Finnish researchers discovered a new anticancer compound using accelerated drug screening process
http://www.pharmanews.eu/research-and-development/1446-finnish-researchers-discovered-a-new-anticancer-compound-using-accelerated-drug-screening-process
Biovision presents its selection of 44 promising life sciences businesses and projects
http://www.pharmanews.eu/conferences-and-events/1445-biovision-presents-its-selection-of-44-promising-life-sciences-businesses-and-projects
AstraZeneca and MRC Laboratory of Molecular Biology to launch joint research fund
http://www.pharmanews.eu/astrazeneca/1444-astrazeneca-and-mrc-laboratory-of-molecular-biology-to-launch-joint-research-fund
Shark antibodies inspire optimization of human antibodies
http://www.pharmanews.eu/research-and-development/1442-shark-antibodies-inspire-optimization-of-human-antibodies
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages